Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Doximity (DOCS) Research & Development (2020 - 2025)

Doximity has reported Research & Development over the past 6 years, most recently at $34.6 million for Q4 2025.

  • Quarterly Research & Development rose 54.3% to $34.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116.4 million through Dec 2025, up 31.7% year-over-year, with the annual reading at $93.0 million for FY2025, 13.48% up from the prior year.
  • Research & Development was $34.6 million for Q4 2025 at Doximity, up from $30.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $34.6 million in Q4 2025 and troughed at $12.6 million in Q1 2021.
  • The 5-year median for Research & Development is $20.3 million (2022), against an average of $21.1 million.
  • Year-over-year, Research & Development surged 56.7% in 2021 and then decreased 6.47% in 2024.
  • A 5-year view of Research & Development shows it stood at $16.2 million in 2021, then increased by 26.47% to $20.5 million in 2022, then fell by 2.79% to $19.9 million in 2023, then rose by 12.41% to $22.4 million in 2024, then soared by 54.3% to $34.6 million in 2025.
  • Per Business Quant, the three most recent readings for DOCS's Research & Development are $34.6 million (Q4 2025), $30.2 million (Q3 2025), and $26.8 million (Q2 2025).